US 12,290,531 B2
Compositions targeting BCMA and methods of use thereof
Michael Curley, Cambridge, MA (US); Ertan Eryilmaz, Cambridge, MA (US); Shawn Jennings, Cambridge, MA (US); LeeAnn Talarico, Cambridge, MA (US); Taylor Hickman, Cambridge, MA (US); Christina Sheau Fen Wong, Cambridge, MA (US); Kathryn Fraser, Cambridge, MA (US); Haiqing Wang, Cambridge, MA (US); and Alessandra Piersigilli, Cambridge, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Apr. 19, 2024, as Appl. No. 18/640,982.
Application 18/640,982 is a continuation of application No. PCT/JP2022/040573, filed on Oct. 19, 2022.
Claims priority of provisional application 63/257,822, filed on Oct. 20, 2021.
Claims priority of provisional application 63/257,846, filed on Oct. 20, 2021.
Prior Publication US 2024/0350544 A1, Oct. 24, 2024
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/42 (2017.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 39/4613 (2023.05); A61K 39/4631 (2023.05); A61K 39/464416 (2023.05); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/42 (2013.01); A61P 35/02 (2018.01); C07K 16/2878 (2013.01); A61K 2239/13 (2023.05); A61K 2239/21 (2023.05); A61K 2239/25 (2023.05); A61K 2239/48 (2023.05); C07K 2317/565 (2013.01)] 6 Claims
 
1. An anti-B-cell maturation antigen (anti-BCMA) antibody or antigen binding fragment thereof, comprising
heavy chain complementarity determining region (CDR) sequences comprising SEQ ID NOs: 2, 3 and 4, and
(a) light chain CDR sequences comprising SEQ ID NOs: 6, 7 and 8; or
(b) light chain CDR sequences comprising SEQ ID NOs: 11, 7 and 14; or
(c) light chain CDR sequences comprising SEQ ID NOs: 11, 7 and 12.